Group 1 - As of February 4, 100 stocks reached a 52-week high, with METROPOLIS CAP (08621), Asia Backup (08290), and Wenling Tooling (01379) leading the high rate at 74.55%, 63.89%, and 57.48% respectively [1] - METROPOLIS CAP closed at 0.048 with a peak of 0.096, while Asia Backup closed at 0.032 with a peak of 0.059, and Wenling Tooling closed at 3.400 with a peak of 6.000 [1] - Other notable stocks that reached new highs include Asia Internet Technology (00679) at 46.23% and Asia Pacific Financial Investment (08193) at 25.45% [1] Group 2 - The 52-week low rankings show that Gaodi Co. (01676) had the largest decline at -45.71%, followed by Xixiang Group (02473) at -23.42% and Jianfa Xingsheng (00731) at -21.51% [3] - Gaodi Co. closed at 0.243 with a low of 0.171, while Xixiang Group closed at 2.370 with a low of 2.060, and Jianfa Xingsheng closed at 0.137 with a low of 0.135 [3] - Other significant declines include Huaxia SOL-R (83460) at -14.34% and Huaxia SOL-U (09460) at -13.97% [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 信達國際控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00111 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,00 ...

Market Overview - The Hong Kong stock index showed mixed performance with the Hang Seng Index rising by 0.09% to 26,773.97 points, while the Hang Seng Tech Index fell by 1.31% to 5,721.82 points [1] - Major tech stocks experienced varied movements, with Alibaba down by 1.25%, Tencent up by 0.92%, and JD.com up by 1.39% [1] - Gold stocks led the rise in the metals sector, with companies like Lingbao Gold and Shandong Gold reaching new highs, while China Nonferrous Mining surged over 11% [1] - Oil stocks strengthened, with CNOOC rising by over 4% [1] - Commercial aerospace stocks generally declined, with Asia Pacific Satellite down over 8% [1] Corporate News - Road King Infrastructure (01098.HK) plans to sell several property rights in the Road King New World commercial project in Ningbo for 100.3 million yuan [2] - Asia Cement (00743.HK) expects a net profit of approximately 85.6 million yuan for 2025 [3] - Zijin Mining (02899.HK) announced the completion of the second phase of the Julong Copper Mine, which will become the largest copper mine in China [4] - Minmetals Capital (01141.HK) anticipates a net profit of 130 million to 170 million HKD for 2025, representing a year-on-year increase of 155.9% to 234.6% [4] - Everbright Securities (06178.HK) projects a revenue of 10.863 billion yuan for 2025, a year-on-year growth of 13.18%, with a net profit of 3.729 billion yuan, up 21.92% [4] - China Merchants Bank (03968.HK) reported a revenue of 337.532 billion yuan for 2025, with a slight increase of 0.01%, and a net profit of 150.181 billion yuan, up by 1.21% [4] - Shanghai Fudan (01385.HK) expects a revenue of approximately 3.93 billion to 4.03 billion yuan for 2025, with a net profit decrease of about 66.82% to 50.58% [4] - China Life Insurance (02628.HK) plans to invest 4 billion yuan to establish a partnership focused on AI-driven technological innovation and industrial upgrades in the Yangtze River Delta [5] - Xinda International Holdings (00111.HK) issued a profit warning, expecting a net profit of approximately 74 million to 82 million HKD [6] - Huadian International Power (01071.HK) reported a cumulative power generation of 262 million MWh for 2025, a decrease of about 6.99% year-on-year [7] - CNOOC Services (02883.HK) released a strategic guideline for 2026, expecting capital expenditure of approximately 8.44 billion yuan [8] - Sinopec (00386.HK) forecasts an oil production of 39.7 million tons for 2025, a slight increase of 0.2%, and a natural gas production of 41.253 billion cubic meters, up 4.02% [8] Institutional Insights - Galaxy Securities noted that the short-term interest rate cut expectations by the Federal Reserve have decreased, leading to a forecast of narrow fluctuations in the Hong Kong stock market [9] - The technology sector remains a long-term investment focus, benefiting from price increases in the supply chain, domestic substitution, and accelerated AI applications [9] - Consumption sectors are expected to continue benefiting from policy support, with attention needed on policy implementation and improvements in consumption data [9] - Dongxing Securities highlighted that the number of satellite launches in China is expected to accelerate by 2026, creating market opportunities in satellite manufacturing and rocket launches [10] - Guangfa Securities indicated that space photovoltaics are likely to benefit from the global commercial aerospace boom, with existing low-orbit satellite plans potentially creating nearly 10 GW of demand for space photovoltaics [10]

主要是由于 (i) 收回一笔疑似呆帐的保证金贷款而回拨金融资产的减值损失;(ii) 由于人民币兑港元升值 而导致本年度未实现汇兑收益增加; 以及(iii)因债券投资组合规模上升致使固定收益投资业务板块之债 券收益上升。 智通财经APP讯，信达国际控股(00111)发布公告，根据集团截至2025年12月31日止年度未经审核综合管 理帐目所作初步审阅，集团预期与截至2024年12月31日止年度录得公司权益持有人应占之综合税后溢利 1034万港元相比，集团于截至2025年12月31日止年度将录得综合净利润约7400万港元至8200万港元。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告之全部或任何部份內容所產生或因依 賴該等內容所引致之任何損失承擔任何責任。 ( 於百慕達註冊成立之有限公司 ) 股東及有意投資人士於買賣本公司股份時務必審慎行事。 本公告乃由信達國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章《證券及期貨條例》（「證券及期貨條例」）第XIVA部內幕消息條文（定義見 上市規則）發出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及有意投資人士，根 據本集團截至2025年12月31日止年度未經審核綜合管理帳目所作初步審閱，本集團預 期與截至2024年12月31日止年度錄得本公司權益持有人應佔之綜合稅後溢利10.34百萬 港元相比，本集團於截至2025年12月31日止年度將錄得綜合淨利潤約74至82百萬港 元，主要是由於 (i) 收回一筆疑似呆帳的保證金貸款而回撥金融資產的減值損失；(ii) 由 於人民幣兌港元升值而導致本年度未實現匯兌 ...

Core Viewpoint - The company Sunflower (300111) has terminated its acquisition of Zhanzhou Xipu Material Technology Co., Ltd. due to an investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][4]. Group 1: Acquisition Details - On September 8, 2025, the company announced a major asset restructuring plan, intending to acquire the controlling stake in Xipu Material and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [2] - The company paid a deposit of 40 million yuan to Shanghai Xipu on September 10, 2025, as part of the acquisition process [2]. - The acquisition was expected to constitute a major asset restructuring and related party transaction, but not a restructuring listing [2]. Group 2: Regulatory Concerns - On December 26, 2025, the Shenzhen Stock Exchange's ChiNext management department issued a letter of concern regarding the operational status of Xipu Material, prompting the company to verify and respond [3][4]. - The ChiNext management raised four key questions regarding Xipu Material's production capacity, financial performance, potential competition issues, and the impact of a lawsuit against its actual controller [4]. Group 3: Termination of Acquisition - On January 14, 2026, the company received a notice of investigation from the CSRC, leading to the termination of the acquisition due to non-compliance with conditions for issuing shares to purchase assets [4]. - The company announced that the termination of the acquisition would not have a significant adverse impact on its operations [4]. Group 4: Refund of Deposit - According to the agreement, if the transaction is terminated, Shanghai Xipu is required to refund the deposit within five working days [5]. - The company sent a collection letter to Shanghai Xipu on January 15, 2026, requesting the refund, and both parties agreed to explore installment repayment or other feasible arrangements [5]. Group 5: Market Performance - As of January 22, the company's stock closed at 4.68 yuan per share, reflecting a 0.86% increase, with a total market capitalization of approximately 6.024 billion yuan [6].

Core Viewpoint - Multiple companies have reported significant profit growth forecasts for 2025, indicating strong performance in sectors such as AI, data communication, and rare earth materials [1][3][5][6][7]. Group 1: Company Performance Forecasts - Changxin Bochuang expects a net profit of 320 million to 370 million yuan for 2025, representing a year-on-year increase of 344.01% to 413.39% [6]. - Shenghong Technology forecasts a net profit of 4.16 billion to 4.56 billion yuan for 2025, with a year-on-year growth of 260.35% to 295.00% [5]. - Northern Rare Earth anticipates a net profit of 2.176 billion to 2.356 billion yuan for 2025, reflecting a year-on-year increase of 116.67% to 134.60% [7]. Group 2: Factors Driving Growth - Changxin Bochuang attributes its profit growth to the rising demand for data communication products driven by cloud computing, AI, and big data technologies [6]. - Shenghong Technology's growth is linked to its strategic focus on AI and data center upgrades, enhancing its position in the global PCB manufacturing sector [5]. - Northern Rare Earth's profit increase is supported by a significant rise in rare earth prices, with notable price increases in various rare earth materials [8]. Group 3: Market Trends - The rare earth market has seen a recovery, with prices for light and heavy rare earths increasing significantly in 2025 [8]. - The average price of neodymium oxide rose by 27.4% year-on-year, while terbium oxide increased by 17.2% [8]. - The price adjustments for rare earth concentrates have been implemented, indicating a continued upward trend in the market [8].

Core Viewpoint - The company Sunflower (SZ300111) has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to the termination of its planned asset acquisition and a significant drop in its stock price [2][6][9]. Group 1: Company Announcement and Stock Impact - On January 14, the company announced it received a notice from the CSRC regarding an investigation into information disclosure violations, resulting in the termination of its planned acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [2][9] - Following the announcement, the company's stock opened with a 20% limit down, with sell orders reaching 1.22 million shares [2]. - The stock price has halved from its peak of 10.28 yuan per share, closing at 4.96 yuan on January 15, with a total market capitalization of 6.385 billion yuan [2][10]. Group 2: Financial Performance - The company focuses on the pharmaceutical sector, specializing in the research, production, and sales of drugs for infections, cardiovascular diseases, and digestive systems [3]. - In the first three quarters of 2025, the company reported revenue of 200 million yuan, a year-on-year decrease of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [3]. Group 3: Acquisition Details and Regulatory Concerns - The planned acquisition involved purchasing 100% of Xipu Materials, which specializes in high-end semiconductor materials, and raising matching funds through share issuance [4]. - Concerns were raised regarding the actual production capacity of Xipu Materials, with media and regulatory scrutiny questioning the operational status of its facilities [4][5]. - The company was required to clarify the production capacity and operational status of its facilities by December 29, 2025, but failed to provide a response by January 15, 2026 [5]. Group 4: Investigation and Future Implications - The CSRC's investigation was prompted by market doubts about the acquisition's viability and potential misleading statements in the restructuring proposal [6][9]. - The company stated that its ongoing operations would not be significantly affected by the investigation or the termination of the acquisition [10]. - Legal experts noted that misleading statements could lead to significant consequences for investor trust and potential claims for damages from affected investors [10].

Core Viewpoint - The company Sunflower (SZ300111) has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to the termination of its planned asset acquisition and restructuring efforts [1][4][7]. Group 1: Investigation and Regulatory Actions - On January 14, the CSRC issued a notice to Sunflower regarding an investigation into the company's information disclosure practices, resulting in a formal case being opened [1][4]. - The company was required to halt its planned acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. due to the investigation [1][7]. - The Shenzhen Stock Exchange raised concerns about the actual production capacity of the acquisition target, Xipu Materials, prompting further scrutiny and a request for additional information from Sunflower [2][3]. Group 2: Financial Impact and Market Reaction - Following the announcement of the investigation, Sunflower's stock price fell to a limit down of 20%, with a trading volume of 1.22 million shares on January 15 [1][7]. - The company's stock price has halved from its peak of 10.28 yuan per share, reflecting significant market volatility and investor concern [1][8]. - Sunflower reported a revenue of 200 million yuan for the first three quarters of 2025, a year-on-year decrease of 12.09%, and a net profit of 1.31 million yuan, down 53.10% year-on-year, indicating financial pressures [1]. Group 3: Business Strategy and Future Outlook - Sunflower aimed to diversify into the semiconductor materials sector due to challenges in its core pharmaceutical business, which has been affected by price declines and competitive bidding risks [7][8]. - Despite the ongoing investigation, the company stated that its production and operational activities remain normal and that the termination of the restructuring will not significantly impact its operations [8].

Core Viewpoint - The Zhejiang Securities Regulatory Bureau has initiated an investigation into Sunflower (300111) due to concerns regarding misleading statements in its restructuring plan, particularly related to the actual production capacity and business model of its acquisition targets [1][2]. Group 1: Investigation and Regulatory Actions - The investigation was prompted by market skepticism regarding the restructuring plan's claims about the production capabilities of the acquired companies [1]. - The China Securities Regulatory Commission (CSRC) will handle the situation based on the findings of the investigation to maintain order in the mergers and acquisitions market [2]. Group 2: Restructuring Plan Details - On September 21, 2025, Sunflower announced a restructuring plan to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., with a share issuance price of 2.93 yuan per share [5]. - Xipu Material is a primary supplier of electronic-grade materials in the semiconductor sector and claims to provide comprehensive fluorine-related services [5]. - Following the announcement, Sunflower's stock price surged, reaching 10.28 yuan per share, with three consecutive trading days of price increases [5]. Group 3: Concerns and Market Reactions - Investigative reports revealed that Xipu Material's factories in Zhangzhou and Lanzhou were not operational, contradicting claims made in the restructuring proposal [5]. - The actual controller of Xipu Material, Chen Chaoqi, has another project, Jiangxi Zhanding, which is also stalled and involved in disputes [5]. - The Shenzhen Stock Exchange issued a letter of concern to Sunflower on December 26, 2025, requesting clarification on the production capacity and operational status of the factories [7]. Group 4: Company Performance - Sunflower's recent financial performance has been weak, with a revenue of 200 million yuan for the first three quarters of 2025, a year-on-year decline of 12.09%, and a net profit of 1.31 million yuan, down 53.10% year-on-year [7]. - As of January 14, 2026, Sunflower's stock closed at 6.20 yuan per share, a decrease of 10%, with a total market capitalization of 7.981 billion yuan [7].